The first complete 3D reconstruction of the compound eye of a minute wasp species sheds light on the nuts and bolts of size reduction.

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that ...

9th Military Vision Symposium on Novel Technology and Vision Restoration hosted by Harvard Medical School Department of Ophthalmology and Mass Eye and Ear, February 27-28, 2025, at the Starr Center ...

The energy resolution limit (ERL) is a mix of parameters representing the economics of a quantum system within a sensor's ...

Lineage Cell Therapeutics, Inc.’s LCTX share price has surged by 14.78%, which has investors questioning if this is right time to sell.

Two new compounds may be able to treat retinitis pigmentosa, a group of inherited eye diseases that cause blindness. The compounds were identified using a virtual screening approach.

Fellow-KI researchers Anders Kvanta and Fredrik Lanner have been awarded a grant of SEK 10 million from the Promobilia ...

SBL03 was formulated as an ophthalmic gel for non-invasive topical delivery. Its unique ability to infiltrate eye tissues effectively and protect ret ...

The Gonzales Lab at UNR Med, led by Albert Gonzales, Ph.D., assistant professor of physiology and cell biology, spearheaded ...

The companies will work together by using the codon-optimized BBS1 AAV9 vector to minimize the vision loss caused by the ...

Australia's Therapeutic Goods Administration has approved the use of a new and first treatment for geographic atrophy - a disease which causes severe ...

Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the closing of the second tranche of its ...